Executive summary of consensus clinical practice guidelines for the prevention of infection in patients with multiple myeloma.
guidelines
infection
myeloma
prevention
Journal
Internal medicine journal
ISSN: 1445-5994
Titre abrégé: Intern Med J
Pays: Australia
ID NLM: 101092952
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
received:
15
06
2022
accepted:
10
04
2023
medline:
22
8
2023
pubmed:
24
4
2023
entrez:
24
04
2023
Statut:
ppublish
Résumé
Infection remains a significant contributor to morbidity and mortality in patients with myeloma. This guideline was developed by a multidisciplinary group of clinicians who specialise in the management of patients with myeloma and infection from the medical and scientific advisory group from Myeloma Australia and the National Centre for Infections in Cancer. In addition to summarising the current epidemiology and risk factors for infection in patients with myeloma, this guideline provides recommendations that address three key areas in the prevention of infection: screening for latent infection, use of antimicrobial prophylaxis and immunoglobulin replacement and vaccination against leading respiratory infections (severe acute respiratory syndrome coronavirus 2, influenza and Streptococcus pneumoniae) and other preventable infections. This guideline provides a practical approach to the prevention of infection in patients with myeloma and harmonises the clinical approach to screening for infection, use of prophylaxis and vaccination to prevent infectious complications.
Substances chimiques
Anti-Infective Agents
0
Types de publication
Practice Guideline
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1469-1477Subventions
Organisme : Medical Research Future Fund
ID : MRF1195894
Organisme : National Health and Medical Research Council
ID : APP1116876
Informations de copyright
© 2023 Royal Australasian College of Physicians.
Références
Australian Institute of Health and Welfare. Cancer data in Australia. Canberra: Australian Government; 2020.
Quach H, Prince HM, Medical Scientific Advisory Group. Clinical Practice Guideline: Multiple Myeloma. Melbourne, Australia: Myeloma Foundation of Australia; 2019.
Teh BW, Harrison SJ, Pellegrini M, Thursky KA, Worth LJ, Slavin MA. Changing treatment paradigms for patients with plasma cell myeloma: impact upon immune determinants of infection. Blood Rev 2014; 28: 75-86.
Bringhen S, Offidani M, Palmieri S, Pisani F, Rizzi R, Spada S et al. Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: a pooled analysis. Crit Rev Oncol Hematol 2018; 130: 27-35.
Teh BW, Harrison SJ, Worth LJ, Spelman T, Thursky KA, Slavin MA. Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy. Br J Haematol 2015; 171: 100-8.
Lim C, Sinha P, Harrison SJ, Quach H, Slavin MA, Teh BW. Epidemiology and risks of infections in patients with multiple myeloma managed with new generation therapies. Clin Lymphoma Myeloma Leuk 2021; 21: 444-450.e3.
Blimark C, Holmberg E, Mellqvist UH, Landgren O, Bjorkholm M, Hultcrantz M et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica 2015; 100: 107-13.
Lin C, Shen H, Zhou S, Liu M, Xu A, Huang S et al. Assessment of infection in newly diagnosed multiple myeloma patients: risk factors and main characteristics. BMC Infect Dis 2020; 20: 699.
Dumontet C, Hulin C, Dimopoulos MA, Belch A, Dispenzieri A, Ludwig H et al. A predictive model for risk of early grade >/= 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial. Leukemia 2018; 32: 1404-13.
Djebbari F, Panitsas F, Eyre TA, Prodger C, Davies F, Burton K et al. Infection-related morbidity in a large study of transplant non-eligible newly diagnosed myeloma patients treated with UK standard of care. Haematologica 2020; 105: e474-9.
Rahman S, Rybicki L, Ky Hamilton B, Pohlman B, Jagadeesh D, Cober E et al. Early infectious complications after autologous hematopoietic cell transplantation for multiple myeloma. Transpl Infect Dis 2019; 21: e13114.
Park H, Youk J, Kim HR, Koh Y, Kwon JH, Yoon SS et al. Infectious complications in multiple myeloma receiving autologous stem cell transplantation in the past 10 years. Int J Hematol 2017; 106: 801-10.
Johnsrud AJ, Johnsrud JJ, Susanibar SA, Kamimoto JJ, Kothari A, Burgess M et al. Infectious and immunological sequelae of daratumumab in multiple myeloma. Br J Haematol 2019; 185: 187-9.
Brioli A, Klaus M, Sayer H, Scholl S, Ernst T, Hilgendorf I et al. The risk of infections in multiple myeloma before and after the advent of novel agents: a 12-year survey. Ann Hematol 2019; 98: 713-22.
Hyun SY, Han SH, Kim SJ, Jang JE, Kim Y, Cho H et al. Pretreatment lymphopenia, poor performance status, and early courses of therapy are risk factors for severe bacterial infection in patients with multiple myeloma during treatment with bortezomib-based regimens. J Korean Med Sci 2016; 31: 510-8.
Teh BW, Worth LJ, Harrison SJ, Thursky KA, Slavin MA. Risks and burden of viral respiratory tract infections in patients with multiple myeloma in the era of immunomodulatory drugs and bortezomib: experience at an Australian cancer hospital. Support Care Cancer 2015; 23: 1901-6.
Cook G, John Ashcroft A, Pratt G, Popat R, Ramasamy K, Kaiser M et al. Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy. Br J Haematol 2020; 190: e83-e6.
Nucci M, Anaissie E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis 2009; 49: 1211-25.
Teh BW, Harrison SJ, Worth LJ, Thursky KA, Slavin MA. Infection risk with immunomodulatory and proteasome inhibitor-based therapies across treatment phases for multiple myeloma: a systematic review and meta-analysis. Eur J Cancer 2016; 67: 21-37.
Ramsey SD, Unger JM, Baker LH, Little RF, Loomba R, Hwang JP et al. Prevalence of hepatitis B virus, hepatitis C virus, and HIV infection among patients with newly diagnosed cancer from academic and community oncology practices. JAMA Oncol 2019; 5: 497-505.
Kurizky PS, dos Santos Neto LL, Aires RB, da Mota LMH, Gomes CM. Opportunistic tropical infections in immunosuppressed patients. Best Pract Res Clin Rheumatol 2020; 34: 101509.
MacLachlan JH, Romero N, Higgins N, Coutts R, Chan R, Stephens N et al. Epidemiology of chronic hepatitis B and C in Victoria, Australia: insights and impacts from enhanced surveillance. Aust N Z J Public Health 2020; 44: 59-64.
Oken MM, Pomeroy C, Weisdorf D, Bennett JM. Prophylactic antibiotics for the prevention of early infection in multiple myeloma. Am J Med 1996; 100: 624-8.
Vesole DH, Oken MM, Heckler C, Greipp PR, Katz MS, Jacobus S et al. Oral antibiotic prophylaxis of early infection in multiple myeloma: a URCC/ECOG randomized phase III study. Leukemia 2012; 26: 2517-20.
Drayson MT, Bowcock S, Planche T, Iqbal G, Pratt G, Yong K et al. Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial. Lancet Oncol 2019; 20: 1760-72.
Satlin MJ, Vardhana S, Soave R, Shore TB, Mark TM, Jacobs SE et al. Impact of prophylactic levofloxacin on rates of bloodstream infection and fever in neutropenic patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2015; 21: 1808-14.
Yeshurun M, Vaxman I, Shargian L, Yahav D, Bishara J, Pasvolsky O et al. Antibacterial prophylaxis with ciprofloxacin for patients with multiple myeloma and lymphoma undergoing autologous haematopoietic cell transplantation: a quasi-experimental single-centre before-after study. Clin Microbiol Infect 2018; 24: 749-54.
Teh BW, Harrison SJ, Worth LJ, Slavin MA. Antiviral prophylaxis for varicella zoster virus infections in patients with myeloma in the era of novel therapies. Leuk Lymphoma 2016; 57: 1719-22.
Glenny AM, Fernandez Mauleffinch LM, Pavitt S, Walsh T. Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer. Cochrane Database Syst Rev 2009: CD006706.
Teh BW, Slavin MA, Harrison SJ, Worth LJ. Prevention of viral infections in patients with multiple myeloma: the role of antiviral prophylaxis and immunization. Expert Rev Anti Infect Ther 2015; 13: 1325-36.
McKay SL, Guo A, Pergam SA, Dooling K. Herpes zoster risk in immunocompromised adults in the United States: a systematic review. Clin Infect Dis 2020; 71: e125-e34.
Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M et al. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med 2018; 379: 1811-22.
Mya DH, Han ST, Linn YC, Hwang WY, Goh YT, Tan DC. Risk of hepatitis B reactivation and the role of novel agents and stem-cell transplantation in multiple myeloma patients with hepatitis B virus (HBV) infection. Ann Oncol 2012; 23: 421-6.
Tsukune Y, Sasaki M, Odajima T, Isoda A, Matsumoto M, Koike M et al. Incidence and clinical background of hepatitis B virus reactivation in multiple myeloma in novel agents' era. Ann Hematol 2016; 95: 1465-72.
Lim C, Sinha P, Harrison SJ, Quach H, Slavin MA, Teh BW. Low rates of invasive fungal disease in patients with multiple myeloma managed with new generation therapies: results from a multi-centre cohort study. Mycoses 2020; 64: 30-4.
Teh BW, Teng JC, Urbancic K, Grigg A, Harrison SJ, Worth LJ et al. Invasive fungal infections in patients with multiple myeloma: a multi-center study in the era of novel myeloma therapies. Haematologica 2015; 100: e28-31.
Tisi MC, Hohaus S, Cuccaro A, Innocenti I, De Carolis E, Za T et al. Invasive fungal infections in chronic lymphoproliferative disorders: a monocentric retrospective study. Haematologica 2017; 102: e108-e11.
Cooley L, Dendle C, Wolf J, Teh BW, Chen SC, Boutlis C et al. Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014. Intern Med J 2014; 44: 1350-63.
Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc 1996; 71: 5-13.
Chen CS, Boeckh M, Seidel K, Clark JG, Kansu E, Madtes DK et al. Incidence, risk factors, and mortality from pneumonia developing late after hematopoietic stem cell transplantation. Bone Marrow Transplant 2003; 32: 515-22.
Teh BW, Yeoh DK, Haeusler GM, Yannakou CK, Fleming S, Lindsay J et al. Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2021. Intern Med J 2021; 51: 67-88.
Musto P, Brugiatelli M, Carotenuto M. Prophylaxis against infections with intravenous immunoglobulins in multiple myeloma. Br J Haematol 1995; 89: 945-6.
Chapel HM, Lee M, Hargreaves R, Pamphilon DH, Prentice AG. Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in multiple myeloma. Lancet 1994; 343: 1059-63.
National Blood Authority. Criteria for the Clinical Use of Immunoglobulin in Australia. Canberra, Australia: National Blood Authority; 2018.
Teh BW, Harrison SJ, Slavin MA, Worth LJ. Epidemiology of bloodstream infections in patients with myeloma receiving current era therapy. Eur J Haematol 2017; 98: 149-53.
Kumar D, Humar A, Plevneshi A, Siegal D, Franke N, Green K et al. Invasive pneumococcal disease in adult hematopoietic stem cell transplant recipients: a decade of prospective population-based surveillance. Bone Marrow Transplant 2008; 41: 743-7.
Chicca IJ, Heaney JLJ, Iqbal G, Dunn JA, Bowcock S, Pratt G et al. Anti-bacterial antibodies in multiple myeloma patients at disease presentation, in response to therapy and in remission: implications for patient management. Blood Cancer J 2020; 10: 114.
Youssef S, Rodriguez G, Rolston KV, Champlin RE, Raad II, Safdar A. Streptococcus pneumoniae infections in 47 hematopoietic stem cell transplantation recipients: clinical characteristics of infections and vaccine-breakthrough infections, 1989-2005. Medicine 2007; 86: 69-77.
Teh BW. Vaccination Schedules. Switzerland: Springer; 2020.
Teh BW, Harrison SJ, Allison CC, Slavin MA, Spelman T, Worth LJ et al. Predicting risk of infection in patients with newly diagnosed multiple myeloma: utility of immune profiling. Front Immunol 2017; 8: 1247.